Carbimazole

Carbimazole is an orally active antithyroid agent which rapidly converts to Methimazole after absorption and prevents thyroid peroxidase enzyme from iodinating and coupling the tyrosine residues on thyroglobulin, hence reducing the production of thyroxine. Carbimazole also displays anti-inflammatory and neuronal-protective activities, suggesting its application for hyperthyroidism and neurological research[1][2][3].

Product Specifications

CAS Number

[22232-54-8]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

P38 MAPK

Type

Reference compound

Related Pathways

MAPK/ERK Pathway

Field of Research

Endocrinology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/carbimazole.html

Purity

99.92

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(N1C=CN(C)C1=S)OCC

Molecular Formula

C7H10N2O2S

Molecular Weight

186.23

Precautions

H302, H315, H319, H335

References & Citations

[1]Nakashima, T. and A. Taurog, Rapid conversion of carbimazole to methimazole in serum; evidence for an enzymatic mechanism. Clin Endocrinol (Oxf), 1979. 10 (6) : p. 637-48.|[2]Lehane C, et al. Carbimazole is an inhibitor of protein synthesis and protects from neuronal hypoxic damage in vitro. J Pharmacol Exp Ther. 2013 Dec;347 (3) :781-93.|[3]H. Saeed, et al. Effects of Dose Level of Anti-thyroid Drug Carbimazole on Thermoregulation and Blood Constituents in Male Rabbits (Oryctolagus cuniculus) . Advances in Research, 2014, 2 (3), 129–144.